The investment will allow BrainBox to do further clinical development of its test, in what the company calls its Headsmart II study. That study is scheduled to start soon and is expected to last about 15 months to 18 months, with up to 2,000 patients who have suffered concussions as a results of sports or accidents. The clinical trial will enable the company to file for FDA approval for its test, said Donna Edmonds, the chief executive officer of BrainBox. UVA Health is among 18 health care sites around the world that will participate in the study.